Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Endometrial Neoplasms 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Lethal Congenital Contracture Syndrome 2 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 20Rituximab 18obinutuzumab 14Lenalidomide 14zanubrutinib 11fludarabine 10Bendamustine Hydrochloride 10Prednisone 8Magnetic Resonance Spectroscopy 8Vincristine 7Doxorubicin 7Specimen Handling 6fludarabine phosphate 5Radiotherapy 4Biopsy 4axicabtagene ciloleucel 3Whole-Body Irradiation 3tisagenlecleucel 2polatuzumab vedotin 2pirtobrutinib 2loncastuximab tesirine 2Therapeutics 2Prednisolone 2Positron Emission Tomography Computed Tomography 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Leukapheresis 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Follicular × Itraconazole × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡